tiprankstipranks
pc:tribu

Tribune Therapeutics

https://tribunetx.com/
Tribune Therapeutics is a biotechnology company focused on developing disease-modifying therapies for fibrotic diseases. The company is advancing its CCN family inhibitor, TRX-44, into clinical trials to address conditions such as idiopathic pulmonary fibrosis (IPF) by targeting the root causes of fibrosis.

Leadership & Board

Current Number of Employees16
Current LinkedIn Followers1,662

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$48M
Total Amount Raised$48M
Total Funding Rounds2
Total Funding Rounds2
Latest Funding Amount$25M
Latest Funding Amount$25M
Latest Funding RoundSeries A
Latest Funding RoundSeries A
Post-Money Valuation
Post-Money Valuation

Employee Trend

Tribune Therapeutics had 16 employees as of May 25, 2026. The number of employees decreased by 1 (5.88%) week-over-week.
16Latest Employee Count
1(-5.88%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.

Social Trend

Tribune Therapeutics had 1,662 followers as of May 25, 2026. The number of followers increased by 4 (0.24%) week-over-week.
1,662Latest Followers Count
4(0.24%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Apr 26, 2025
Series A
$24.80M
Mar 26, 2025
Series A
$23.00M

Investors

Investor Name
Funding Round

Related News and Analysis